The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2018 | RUXOPEG: a promising novel combination for MPN-associated myelofibrosis
Jean-Jacques Kiladjian, MD, PhD, of Saint-Louis Hospital & Paris Diderot University, Paris, France, discusses the RUXOPEG trial (NCT02742324) of ruxolitinib and pegylated interferon alpha 2a for myeloproliferative neoplasm-associated myelofibrosis. Prof. Kiladjian covers the initial efficacy and safety results of this novel combination from the first study to formally assess this, before explaining further plans for this regimen. This interview took place at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.
